Today: 7 February 2026
Subscribe
Browse Category

NYSE:HXL News 11 December 2025 - 29 January 2026

Hexcel Stock (NYSE: HXL) Near 52‑Week High: Analyst Ratings, Forecasts and Q3 2025 Outlook – December 11, 2025

Hexcel Stock (NYSE: HXL) Near 52‑Week High: Analyst Ratings, Forecasts and Q3 2025 Outlook – December 11, 2025

Published: December 11, 2025 – All data as of market hours on this date unless otherwise stated. Hexcel stock today: trading just under record highs Hexcel Corporation, the aerospace composites specialist supplying Boeing, Airbus and defense primes, is trading close to its all‑time high as investors weigh strong long‑term demand against a stretched valuation. As of December 11, 2025, Hexcel stock (NYSE: HXL) is changing hands at about $76.4 per share, after closing at the same level in the prior session. The stock has traded in a day range roughly between $75.6 and $76.8, with a 52‑week range of $45.28
11 December 2025
··

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop